EMP2 and neoplasm: Our group has evidence that inhibition of EMP2 through antibody blockade is effective in other models of angiogenesis, including corneal neovascularization13 and proliferative vitreoretinopathy20 as well as animal tumor models of glioblastoma and breast cancer19,26,27.